Which treatment is considered a disease-modifying agent for rheumatoid arthritis?

Methotrexate is recognized as a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. Its primary function is to slow the progression of the disease and prevent joint damage by modifying the immune system's response. Unlike non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or analgesics such as acetaminophen, which primarily provide symptomatic relief, methotrexate has a direct impact on the underlying pathophysiology of rheumatoid arthritis.

Additionally, corticosteroids like prednisone can alleviate inflammation and reduce symptoms but do not modify the disease course. Thus, while they may provide short-term relief of symptoms, they do not reduce the long-term effects of rheumatoid arthritis or prevent joint damage. Methotrexate, however, is effective in achieving remission and improving function in patients with this condition, which solidifies its role as a disease-modifying treatment.